| Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. | |
| | |
| Jump to Full Text | |
MedLine Citation:
|
PMID: 7640219 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The expression of epidermal growth factor receptor (EGFR), oestrogen receptor (ER) and progesterone receptor (PR) was assayed by a radioreceptor method in 117 primary ovarian cancers. EGFR was not significantly related to any of the clinicopathological parameters examined. In patients with stage II-IV disease who underwent second-look surgery after primary chemotherapy, a significant correlation between high EGFR levels and poor response to chemotherapy was demonstrated (P = 0.031). Moreover, post-operative residual tumour showed an independent role in predicting chemotherapy response (P = 0.0007) and EGFR status showed a borderline significance (P = 0.052) in the multivariate analysis. No correlation between steroid hormone receptors and clinicopathological parameters was observed. Whereas a significant relationship was shown between EGFR positivity and a shorter overall survival (OS) (P = 0.0022) and progression-free survival (PFS) (P = 0.0033), patient survival was not related to steroid hormone receptor status. Among the parameters tested only stage, ascites and EGFR status retained an independent prognostic value in the multivariate analysis. |
| | |
Authors:
|
G Scambia; P Benedetti-Panici; G Ferrandina; M Distefano; G Salerno; M E Romanini; A Fagotti; S Mancuso |
Related Documents
:
|
15569989 - A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. 15138369 - Successful targeted radiotherapy with 90y-dotatoc in a patient with merkel cell carcino... 12180239 - Prognostic significance of estrogen receptor expression in superficial transitional cel... 3835979 - Elastosis and steroid receptors in primary breast cancer. 9624239 - Very low-dose adjuvant chemotherapy in steroid receptor negative stage i breast cancer ... 10915729 - Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in t... 17595779 - Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer... 11812959 - Roles of the glucocorticoid receptor in resectable hepatocellular carcinoma. 23589709 - Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: British journal of cancer Volume: 72 ISSN: 0007-0920 ISO Abbreviation: Br. J. Cancer Publication Date: 1995 Aug |
Date Detail:
|
Created Date: 1995-09-21 Completed Date: 1995-09-21 Revised Date: 2010-09-13 |
Medline Journal Info:
|
Nlm Unique ID: 0370635 Medline TA: Br J Cancer Country: SCOTLAND |
Other Details:
|
Languages: eng Pagination: 361-6 Citation Subset: IM |
Affiliation:
|
Department of Gynecology and Obstetrics, Catholic University, Rome, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antineoplastic Agents / therapeutic use* Female Follow-Up Studies Humans Middle Aged Neoplasm Staging Ovarian Neoplasms / drug therapy*, pathology, ultrastructure* Prognosis Prospective Studies Radioligand Assay Receptor, Epidermal Growth Factor / analysis* Receptors, Estrogen / analysis* Receptors, Progesterone / analysis* Survival Analysis Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Receptors, Estrogen; 0/Receptors, Progesterone; EC 2.7.10.1/Receptor, Epidermal Growth Factor |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
| Full Text | |
|
Journal Information Journal ID (nlm-ta): Br J Cancer ISSN: 0007-0920 ISSN: 1532-1827 |
Article Information Download PDF  Print publication date: Month: 8 Year: 1995 Volume: 72 Issue: 2 First Page: 361 Last Page: 366 ID: 2033999 PubMed Id: 7640219 |
| Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. | |
| G. Scambia | |
| P. Benedetti-Panici | |
| G. Ferrandina | |
| M. Distefano | |
| G. Salerno | |
| M. E. Romanini | |
| A. Fagotti | |
| S. Mancuso | |
| Department of Gynecology and Obstetrics, Catholic University, Rome, Italy. |
|
Article Categories:
|
|
Previous Document: Prognostic value of bcl-2 expression in invasive breast cancer.
Next Document: Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours.